KTTA

Pasithea Therapeutics Corp

0.4049

Oct 23 • 3:59 PM ET -0.0403 (-9.05%)

0.3952

Aftermarket • 5:00 PM ET -0.0097 (-2.40%)

Healthcare Biotechnology USA Nano NASD

Oct 23, 9:20 AMPasithea Therapeutics reports positive Phase 1 PAS-004 MEK inhibitor data in advanced solid tumors, with prolonged stable disease and favorable safety at ESMO 2026

Peers: ERAS BDTX OKUR ACTU KZIA BOLD TYRA MBRX PRLD CRIS

| Held by: PSIL VXF

Scroll to Statements

Index	-
Market Cap	13.53M
Enterprise Value	-32.24M
Income	-21.29M
Sales	0.00M
Book/sh	1.49
Cash/sh	1.37
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	5
IPO	Sep 15, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.27
P/C	0.30
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	26.25
Current Ratio	26.25
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-1.58
EPS next Y	-0.46
EPS next Q	-0.21
EPS this Y	73.88%
EPS next Y	39.47%
EPS next 5Y	42.61%
EPS past 3/5Y	35.92% -117.71%
Sales past 3/5Y	- -
EPS Y/Y TTM	79.07%
Sales Y/Y TTM	-
EPS Q/Q	75.06%
Sales Q/Q	-
Earnings	Sep 02
EPS/Sales Surpr.	0.00% -

Insider Own	3.59%
Insider Trans	9.09%
Inst Own	60.32%
Inst Trans	1.28%
ROA	-61.97%
ROE	-65.49%
ROIC	-42.72%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-9.55%
SMA50	-18.55%
SMA200	-37.22%
Trades

Shs Outstand	33.41M
Shs Float	32.21M
Short Float	0.50%
Short Ratio	0.78
Short Interest	0.16M
52W High	2.06 -80.34%
52W Low	0.28 44.09%
Volatility	15.35% 9.49%
ATR (14)	0.04
RSI (14)	39.58
Beta	0.36
Rel Volume	7.47
Avg Volume	205.41K
Volume	1,533,408

Perf Week	-3.60%
Perf Month	-21.18%
Perf Quarter	-10.02%
Perf Half Y	-41.32%
Perf YTD	-68.61%
Perf Year	-44.53%
Perf 3Y	-95.36%
Perf 5Y	-99.25%
Perf 10Y	-
Recom	1.00
Target Price	3.00
Prev Close	0.45
Price	0.40
Change %	-9.05%

Oct-23-26 09:15AM	Pasithea Therapeutics Announces Positive PAS-004 Clinical Data from Phase 1 Advanced Cancer Study Presented at ESMO Congress 2026 (GlobeNewswire) -9.05%
Sep-14-26 07:00AM	Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference (GlobeNewswire)
Sep-03-26 04:05PM	Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences (GlobeNewswire)
Jul-21-26 07:00AM	Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026 (GlobeNewswire)
Jul-08-26 07:02AM	Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit (GlobeNewswire)
07:00AM	Loading…
Jun-30-26 07:00AM	Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion (GlobeNewswire)
Jun-16-26 07:00AM	Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial (GlobeNewswire) -8.93%
Jun-15-26 07:02AM	Pasithea Therapeutics Announces Exhibit at Children's Tumor Foundation 2026 NF Conference (GlobeNewswire) -5.26%
Jun-02-26 07:02AM	Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS) (GlobeNewswire) -9.79%
May-04-26 07:01AM	Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer (GlobeNewswire)
Apr-20-26 07:01AM	Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) (GlobeNewswire)
Apr-01-26 07:01AM	Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity (GlobeNewswire)
Feb-17-26 07:01AM	Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-13-26 07:01AM	Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines (GlobeNewswire)
Dec-02-25 07:00AM	Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock (GlobeNewswire)
08:38AM	Loading…
Dec-01-25 08:38AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive) -21.09%
Nov-28-25 09:20AM	Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock (GlobeNewswire) +38.68%
Nov-25-25 07:00AM	Pasithea Therapeutics Announces $1 Million Award by ALS Association to Study the Efficacy, Safety, and Tolerability of PAS-004 for Treatment of ALS (GlobeNewswire) +14.78%
Nov-24-25 07:00AM	Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) Data (GlobeNewswire) +45.33%
Nov-21-25 12:35PM	Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients (GlobeNewswire) -29.58%
Nov-20-25 04:01PM	Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study (GlobeNewswire) -12.78%
Nov-04-25 07:03AM	Pasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 Patients (GlobeNewswire) -5.87%
Sep-16-25 07:03AM	Pasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 Patients (GlobeNewswire)
Sep-08-25 07:01AM	Pasithea Therapeutics Announces Enrollment of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for its Ongoing Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients (GlobeNewswire)
Aug-29-25 08:39AM	Pasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-28-25 07:02AM	Pasithea Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire) +11.76%
Jul-31-25 07:01AM	Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients (GlobeNewswire)
Jun-11-25 07:02AM	Pasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory Board (GlobeNewswire)
Jun-02-25 08:02AM	Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025 (GlobeNewswire)
May-20-25 07:01AM	Pasithea Therapeutics Announces Preclinical Data that Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market Diseases (GlobeNewswire)
07:02AM	Loading…
May-14-25 07:02AM	Pasithea Therapeutics Announces Initiation of Phase 1/1B Study of PAS-004 in Adult NF1 Patients and Activation of First Clinical Trial Site (GlobeNewswire) +11.07%
May-07-25 05:00PM	Pasithea Therapeutics Announces Closing of $5 Million Public Offering (GlobeNewswire) -25.66% -15.04%
11:35AM	Pasithea Therapeutics 3.57M share Secondary priced at $1.40 (TipRanks)
May-06-25 11:10AM	Pasithea Therapeutics Announces Pricing of $5 Million Public Offering (GlobeNewswire) +7.04%
07:03AM	Pasithea Therapeutics Reports Positive Pharmacodynamic Results Demonstrating Robust Target Engagement from its Ongoing Phase 1 Clinical Trial of PAS-004 (GlobeNewswire)
Apr-29-25 07:02AM	Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer Patients (GlobeNewswire)
Apr-24-25 07:02AM	Pasithea Therapeutics to Present Updated Data from Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients at the 2025 ASCO Annual Meeting (GlobeNewswire) +5.52%
Apr-10-25 07:02AM	Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer (GlobeNewswire) +46.79%
Mar-24-25 06:59AM	Pasithea Therapeutics to Present at the 2025 CAGLA NeauxCancer Conference (GlobeNewswire)
Feb-05-25 06:59AM	Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer (GlobeNewswire) +31.73%
Jan-14-25 08:02AM	Pasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4 (GlobeNewswire)
Nov-20-24 07:02AM	Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer (GlobeNewswire)
Sep-26-24 06:44PM	Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) +52.15%
07:02AM	Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer (GlobeNewswire)
Sep-09-24 08:01AM	Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies (GlobeNewswire)
Sep-03-24 08:02AM	Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board (GlobeNewswire) +6.57%
Aug-28-24 09:11AM	Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Jun-25-24 12:52PM	KTTA Stock Earnings: Pasithea Therapeutics Reported Results for Q4 2023 (InvestorPlace) +6.64%
Jun-13-24 06:59AM	Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for PAS-004 in Ongoing Phase 1 Clinical Trial (GlobeNewswire)
May-28-24 06:59AM	Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting (GlobeNewswire)
May-15-24 09:53AM	KTTA Stock Earnings: Pasithea Therapeutics Reported Results for Q1 2024 (InvestorPlace)
Apr-29-24 07:59AM	Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting (GlobeNewswire)
Apr-24-24 07:59AM	Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers (GlobeNewswire)
Apr-15-24 11:00AM	11 Undervalued Stocks for Less Than $50 in April 2024 (Investopedia)
Feb-13-24 07:59AM	Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004 (GlobeNewswire) +8.95%
Jan-08-24 07:59AM	Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position (GlobeNewswire) +5.03%
Jan-02-24 08:35AM	Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients (GlobeNewswire) +8.78%
Dec-28-23 05:00PM	Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023 (GlobeNewswire) -5.13%
Dec-19-23 05:19PM	Pasithea Therapeutics Announces Results from 2023 Annual Meeting (GlobeNewswire) -6.06% -13.61%
Dec-13-23 09:03AM	Why Is Pasithea Therapeutics (KTTA) Stock Down 12% Today? (InvestorPlace)
Dec-11-23 11:18AM	Why Is Pasithea Therapeutics (KTTA) Stock Up 105% Today? (InvestorPlace) +47.42%
08:01AM	Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models (GlobeNewswire)
Nov-29-23 04:27PM	Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders (GlobeNewswire) +6.63% -7.91%
07:59AM	Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical Development (GlobeNewswire)
Nov-09-23 07:59AM	Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets 5 1 Integrin for the Treatment of both Sporadic and Familial ALS (GlobeNewswire)
Sep-14-23 08:30AM	Pasithea Therapeutics Corp. Announces Final Results of Tender Offer (GlobeNewswire)
Sep-07-23 04:14PM	Pasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire) -13.18%
Aug-01-23 07:59AM	Pasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in 5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting 5 integrin results in improved survival and motor function (GlobeNewswire)
Jul-31-23 06:00AM	The Psychedelics Stock Universe Is Shrinking, Despite the Hype (Bloomberg)
Jul-20-23 08:43AM	Pasithea Therapeutics Announces Intention to Commence a $4.0 Million Tender Offer for its Common Stock at Price of $0.70 per Share in Cash (GlobeNewswire) +25.88%
08:40AM	Pasithea Therapeutics Special Committee Rejects Unsolicited Bid from Lucy Scientific Discovery, Inc. (GlobeNewswire)
Jul-13-23 09:14AM	Lucy Scientific Scores Richard Nanula as CEO After Senior Roles at Disney, Amgen, Starwood (Exec Edge)
Jun-30-23 09:28AM	Pasithea Therapeutics Confirms Previous Creation of Independent Special Committee of its Board of Directors (GlobeNewswire)
Jun-29-23 02:50PM	Lucy Scientific Discovery Reiterates Its Proposal to Acquire Pasithea Therapeutics Corp. (GlobeNewswire) +11.24%
08:29AM	Pasithea Therapeutics Announces Completion of GMP Manufacturing for PAS-004 (GlobeNewswire)
Jun-06-23 04:30PM	Pasithea Therapeutics Confirms Receipt of Unsolicited Proposal from Lucy Scientific Discovery Inc. (GlobeNewswire)
Jun-05-23 09:00AM	Lucy Scientific Discovery Announces Proposal to Acquire Pasithea Therapeutics Corp. (GlobeNewswire) +25.00%
Jun-01-23 07:57AM	Pasithea Therapeutics Abstract Accepted for Poster Presentation at 2023 Neurofibromatosis Conference (GlobeNewswire)
May-14-23 08:13AM	Pasithea Therapeutics First Quarter 2023 Earnings: US$0.13 loss per share (vs US$0.068 loss in 1Q 2022) (Simply Wall St.)
May-03-23 08:26AM	Pasithea Therapeutics to Participate in EF Hutton Inaugural Global Conference (GlobeNewswire)
Mar-02-23 08:00AM	Pasithea Therapeutics Chairman, Prof. Lawrence Steinman, to Deliver Keynote Address at the American Association for Advancement of Science (AAAS) Annual Meeting (GlobeNewswire)
Feb-23-23 08:00AM	Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Deliver Dr. Kenneth P. Johnson Lecture at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) (GlobeNewswire) -5.64%
Feb-16-23 07:30AM	Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Receive Pioneer in Medicine Award (GlobeNewswire)
Jan-18-23 08:00AM	Pasithea Therapeutics Signs CMC Development and Manufacturing Agreement for the Production of PAS-004 (GlobeNewswire)
Dec-14-22 05:18PM	Majority of Stockholders Support Pasithea Directors at Special Meeting (GlobeNewswire)
Dec-12-22 07:00AM	Pasithea Therapeutics Announces Comprehensive Settlement Agreement with the Camac Group (GlobeNewswire) -8.22%
Dec-07-22 04:00PM	Investor Group Recommends Stockholders Vote the WHITE Proxy Card for Boardroom Change at Pasithea Therapeutics (Business Wire)
Dec-06-22 08:00AM	Pasithea Therapeutics to Present at Annual Meeting of the Antibody Society Conference (GlobeNewswire)
Nov-28-22 07:05PM	Pasithea Therapeutics Postpones Special Meeting until December 9, 2022 at 9:00 AM Eastern Time (GlobeNewswire)
Nov-22-22 04:00PM	Investor Group Recommends Stockholders Vote the WHITE Proxy Card for Boardroom Change at Pasithea Therapeutics (Business Wire)
Oct-27-22 09:50AM	A New BioTech Research Race Is Focused On Improving Life For MS Patients (News Direct)
Oct-17-22 08:00AM	Pasithea Therapeutics to Present Tolerizing Vaccine Program Results at Immunotherapy 2022 International Course and Symposium (GlobeNewswire) -11.20%
Oct-14-22 09:48AM	Pasithea' Largest Investor Group Says AlloMek Therapeutics Deal Ill-timed, Highly Dilutive (Benzinga)
Oct-13-22 04:00PM	Investor Group Comments on Pasithea Therapeutics Seemingly Defensive and Ill-Timed Acquisition of AlloMek Therapeutics (Business Wire)
Oct-12-22 08:00AM	Pasithea Therapeutics Acquires AlloMek Therapeutics (GlobeNewswire)
07:31AM	EXCLUSIVE: Pasithea Bolsters CNS-Focused Pipeline With AlloMek Therapeutics Acquisition (Benzinga)
Oct-10-22 09:39AM	New Drugs And Therapies Are Giving MS And ALS Sufferers New Hope (News Direct)
Oct-03-22 06:03PM	Pasithea Therapeutics to Call Special Meeting of Stockholders (GlobeNewswire)
09:09AM	Biotech Company Pleased With Results Of Early Testing Demonstrating Vaccine Potential For Multiple Sclerosis (News Direct)
Sep-28-22 09:00AM	Investor Group Sends Letter to Pasithea Therapeutics Board of Directors (Business Wire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Coastlands Capital LP	10% Owner	Jun 17 '26	Buy	0.53	100,000	53,000	3,835,035	Jun 22 10:30 AM
STEINMAN LAWRENCE	Director	Nov 28 '25	Buy	0.75	133,333	100,000	199,691	Dec 01 09:07 AM
Marques Tiago	Chief Executive Officer	Nov 28 '25	Buy	0.75	33,333	25,000	73,334	Dec 01 08:56 AM
Dumesnil Simon	Director	Nov 28 '25	Buy	0.75	33,333	25,000	35,833	Dec 01 08:54 AM

Pasithea Therapeutics Corp. is a biotechnology company focused on the research and discovery of new and treatments for psychiatric and neurological disorders. The company was founded by Yassine Bendiabdallah and Lawrence J. Steinman on May 12, 2020 and is headquartered in Miami Beach, FL.

M.D.Dr. Lawrence Steinman BA

Ph.D.Dr. Tiago Reis Marques M.D.

Chief Financial OfficerMr. Daniel H. Schneiderman

Ph.D.Dr. Kartik Krishnan M.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

KTTA

Pasithea Therapeutics Corp

Upgrade your Finviz experience